The COVID-19 pandemic has severely influenced all aspects of life in 2020. This pandemic
also affected patients with rheumatic and musculoskeletal diseases (RMDs) and impacted …

The COVID-19 pandemic has significantly impacted the care and personal lives of people
with rheumatic and musculoskeletal diseases (RMDs). Vaccination against COVID-19 has …

Vaccination against SARS-CoV-2 has become available and will hopefully end the current
pandemic. Understandably, patients with inflammatory rheumatic diseases (iRMDs) and …

Since January 2020, the whole world has been facing the worst epidemic for a century.
SARS-CoV-2 infection has so far caused more than one million deaths, with the only …

Similarly to the general population, advanced age, comorbidities and chronic glucocorticoid
treatment (≥ 10 mg/day prednisoneequivalent) have been identified as negative prognostic …

SARS-CoV-2 vaccines appear to be the most promising strategy for fighting the virus and
protecting also those who might be at higher risk of severe COVID-19, such as patients with …

The first EULAR provisional recommendations on the management of rheumatic and
musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome …

In view of the COVID-19 pandemic, there is an unmet clinical need for the guidelines on
vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD). This …

Introduction In light of the SARS-CoV-2 pandemic, protecting vulnerable groups has become
a high priority. Persons at risk of severe disease, for example, those receiving …

We read with interest the recent report by Geisen et al, 1 who describe the immunogenicity
and safety profile of two mRNA-based anti-SARS-CoV-2 vaccines in a cohort of 26 patients …